Abstract: The present invention relates to dendritic cell and cell mixture which is capable of suppressing T cell-dependent immune response specific for an antigen. The dendritic cell according to the present invention is a dendritic cell capable of suppressing T cell-dependent immune response specific for an antigen, which presents antigen fragment of said antigen which is presented against T cell in said immune response, and ?-glycosylceramide derivative. The cell mixture according to the present invention is a cell mixture capable of suppressing T cell-dependent immune response specific for an antigen, which comprises dendritic cells presenting at least antigen fragment of said antigen which is presented against T cell in said immune response, and dendritic cells presenting at least ?-glycosylceramide derivative.

Abstract: This invention provides a growth inhibitor of human hepatitis C virus comprising, as an active ingredient, ?-glycosylceramide used for patients infected with the aforementioned viruses. This inhibitor of hepatitis C virus comprises, as an active ingredient, a compound represented by formula (I) or a salt or solvate thereof.

Abstract: This invention provides: a therapeutic agent for graft rejection, graft-versus-host disease, autoimmune disease, allergic disease, or other diseases comprising dendritic cells (DCs) induced under culture conditions comprising both IL-10 and TGF-? or DCs prepared by adding inflammatory stimulation (e.g., TNF-? or LPS) to the aforementioned DCs and, if necessary, an antigen associated with a target disease; a method of inducing human immunoregulatory dendritic cells by culturing human dendritic cells or their precursor cells in vitro with cytokines comprising at least IL-10 and TGF-?; human immunoregulatory dendritic cells obtained by such method; and a pharmaceutical composition comprising such human immunoregulatory dendritic cells.

Abstract: The present invention provides an agent for treatment of arthritic diseases such as rheumatoid arthritis that has for its active ingredient a complex of hyaluronic acid and zinc. This complex synergistically inhibits proliferation of synovial cells and suppresses matrix metalloproteinase MMP-9, which is produced by synovial cells, as compared with its constituents, hyaluronic acid and zinc, alone.